Mylan Must Divest Two Generics To Buy Meda, FTC Says
The Federal Trade Commission on Tuesday cleared the way for drugmaker Mylan NV's $7.2 billion acquisition of Swedish drugmaker Meda AB, provided Mylan divests assets for two generic drugs in order...To view the full article, register now.
Already a subscriber? Click here to view full article